
1. top antivir med. 2014 jan;21(5):157-63.

an update hepatitis b, d, e viruses.

price j(1).

author information: 
(1)university california san francisco, san francisco, ca, usa.

although newer effective treatments available hepatitis c
virus (hcv) infection, non-hcv viral hepatitis remains important cause of
liver disease, especially among hiv-infected individuals. hepatitis b virus (hbv)
is leading cause cirrhosis worldwide, approximately one-quarter of
patients cirrhosis develop decompensated liver disease within 5 years.
initial treatment chronic hbv infection includes peginterferon alfa,
entecavir, tenofovir. approximately 15 million estimated 350 million
individuals chronic hbv infection evidence exposure hepatitis d
(delta) virus (hdv), requires hepatitis b surface antigen transmission 
and packaging. hbv/hdv coinfection associated severe acute hepatitis
and higher mortality acute hbv monoinfection. chronic coinfection is
associated higher risk cirrhosis decompensated liver disease. the
mainstay treatment hdv infection peginterferon alfa least 48
weeks. cases hepatitis e virus (hev) infection hiv-infected persons have
been reported. hev infection become chronic immunosuppressed patients, and
chronic infection associated rapid development cirrhosis. no
established guidelines treating hev infection hiv-infected persons. this
article summarizes presentation jennifer price, md, ias-usa
continuing education program held san francisco, california, june 2013.


pmcid: pmc6148847
pmid: 24531556  [indexed medline]

